Safety and immunogenicity of a monovalent MF59®-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults.

Authors:
Address: University Department of Pediatrics, DPUO, Clinical Trial Center Unit, Bambino Gesù Children's Hospital, Piazza S, Onofrio 4, 00165 Rome, Italy. paolo.palma@opbg.net
Journal:

Publication:

abstract

BACKGROUND:

This Phase IV study evaluated the Safety and immunogenicity of a two-dose, MF59®-adjuvanted (Novartis vaccines, Marburg, Germany), monovalent, A/H1N1 pandemic influenza vaccination schedule in Human Immunodeficiency Virus (HIV) positive children and young adults.

METHODS:

A total of 83 children infected with HIV-1, and 37 non-immunocompromised, age-matched controls were enrolled. All participants received two vaccine doses administered three weeks apart. Antibody responses were assessed by haemagglutination assay at baseline, three weeks after each vaccine dose, and six months after immunization. Vaccines were evaluated according to European influenza vaccine licensure criteria.

RESULTS:

The investigational vaccine was well tolerated. After the first vaccine dose, seroconversion rates were significantly lower in HIV-positive patients (60%) than controls (82%), with GMTs of 419 and 600, respectively. No significant differences in seroconversion rates were observed between the two study groups in response to the second vaccine dose. Persisting antibody titers were similar for both HIV-positive and non-infected controls, six months after immunization.

CONCLUSION:

One dose of MF59-adjuvanted vaccine was sufficient to provide adequate levels of seroprotection against A/H1N1 influenza disease in HIV-positive children. However, a two-dose vaccination schedule may be optimal for this population.

Related Articles
A Dose-Range Study of MF59®-Adjuvanted Versus Non-Adjuvanted Monovalent A/H1N1 Pandemic Influenza Vaccine in 6 to <36 Month-Old Children.
Pediatr Infect Dis J. 2012
A Dose-Range Study of MF59®-Adjuvanted Versus Non-Adjuvanted Monovalent A/H1N1 Pandemic Influenza Vaccine in 6 to <36 Month-Old Children.
Block SL, Ruiz-Palacios GM, Guerrero ML, Beygo J, Sales V, Holmes SJ. Pediatr Infect Dis J. 2012 Apr 4; . Epub 2012 Apr 4.
Identification of Antigen and Adjuvant Doses Resulting in Optimal Immunogenicity and Antibody Persistence up to One Year After Immunization with a Pandemic A/H1N1 Influenza Vaccine in Children 3 to < 9 Years of Age.
Pediatr Infect Dis J. 2012
Identification of Antigen and Adjuvant Doses Resulting in Optimal Immunogenicity and Antibody Persistence up to One Year After Immunization with a Pandemic A/H1N1 Influenza Vaccine in Children 3 to < 9 Years of Age.
Nassim C, Christensen S, Henry D, Holmes S, Hohenboken M, Kanesa-Thasan N. Pediatr Infect Dis J. 2012 Feb 1; . Epub 2012 Feb 1.
Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.
Vaccine. 2012
Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.
Vesikari T, Forstén A, Herbinger KH, Cioppa GD, Beygo J, Borkowski A, Groth N, Bennati M, von Sonnenburg F. Vaccine. 2012 Feb 8; 30(7):1388-96. Epub 2011 Dec 20.
Review Immunogenicity and safety of pandemic influenza A (H1N1) 2009 vaccine: systematic review and meta-analysis.
Influenza Other Respi Viruses....
Review Immunogenicity and safety of pandemic influenza A (H1N1) 2009 vaccine: systematic review and meta-analysis.
Yin JK, Khandaker G, Rashid H, Heron L, Ridda I, Booy R. Influenza Other Respi Viruses. 2011 Sep; 5(5):299-305. Epub 2011 Mar 21.
Review MF59 adjuvanted seasonal and pandemic influenza vaccines.
Yakugaku Zasshi. 2011
Review MF59 adjuvanted seasonal and pandemic influenza vaccines.
Tsai TF. Yakugaku Zasshi. 2011; 131(12):1733-41.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.